Drugs

FDA announces Pharmakon Pharmaceuticals’ nationwide voluntary recall of purportedly sterile drug products

[5/6/2016] FDA is alerting health care professionals of a voluntary recall of all non-expired drug compounded products intended to be sterile and distributed nationwide by Pharmakon Pharmaceuticals, Inc., of Noblesville, Indiana, due to a lack of sterility assurance and other quality issues.

These compounded products are used for a variety of indications and are packaged in bags, syringes and cad cassettes. All recalled products have a label that includes the Pharmakon Pharmaceuticals, Inc., name, address and expiration date. The products were distributed nationwide to hospitals from March 4, 2016, to April 15, 2016.

Health care professionals should immediately check their medical supplies, quarantine any drug products marketed as sterile from Pharmakon, and not administer them to patients. Administration of a non-sterile drug product intended to be sterile may result in serious and potentially life-threatening infections or death.

Pharmakon’s customers can contact the company at 888-660-6715 x251 between 8:30 a.m. and 5 p.m. Eastern Standard Time Monday through Friday to discuss the return of any unused compounded drug products marketed as sterile.

FDA encourages health care professionals and patients to report adverse reactions or quality problems to FDA’s MedWatch Adverse Event Reporting program:

Pharmakon Pharmaceuticals, Inc. is registered under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) as an outsourcing facility.


FDA alerts health care professionals not to use sterile drug products from Pharmakon Pharmaceuticals Inc., Noblesville, Indiana

[4/15/2016] The U.S. Food and Drug Administration is alerting health care professionals not to use any drug products that are intended to be sterile and are produced and distributed nationwide by Pharmakon Pharmaceuticals Inc., in Noblesville, Indiana, due to a lack of sterility assurance and other quality issues.

Health care professionals should immediately check their medical supplies, quarantine any drug products marketed as sterile from Pharmakon, and not administer them to patients. Administration of a non-sterile drug product intended to be sterile may result in serious and potentially life-threatening infections or death.

FDA recently inspected Pharmakon’s facility following the company’s voluntary recall of super-potent morphine sulfate 0.5 mg/ml preservative free in 0.9% sodium chloride, 1 ml syringe, CII, for intravenous use. FDA test results showed the product to be nearly 2,500 percent the labeled potency. During the inspection, investigators observed insanitary conditions, including poor sterile production practices, and other deficiencies, which raise concerns about Pharmakon’s ability to assure the sterility and quality of drug products that it produces. Additionally, FDA testing confirmed environmental contamination on multiple sites within the clean rooms, including the critical ISO-5 area.

On April 11, 2016, FDA recommended that Pharmakon cease sterile operations until appropriate corrective actions have been implemented by the facility and recall all non-expired drug products that are intended to be sterile. On April 12, 2016, Pharmakon informed FDA that it would neither initiate a recall nor cease sterile production. Therefore, FDA is alerting health care professionals not to use drug products marketed as sterile from Pharmakon.

Additionally, on February 16, 2016, FDA received reports of serious adverse events experienced by three infants associated with the use of the recalled super-potent morphine sulfate products from Pharmakon. Injecting a patient with super-potent morphine could result in serious consequences including respiratory depression, coma, and death. Patients who have received this drug product and have concerns should contact their health care professionals. To date, FDA is not aware of any additional reports of illness associated with the use of these products.

FDA encourages health care professionals and patients to report adverse reactions or quality problems to FDA’s MedWatch Adverse Event Reporting program:

FDA conducted its initial inspection of Pharmakon in March 2014. A second inspection was conducted in April 2014 to follow up on adverse event reports related to super-potent midazolam products administered to neonatal infants. Based on the observations made during the 2014 inspections, FDA issued a warning letter in May 2015. Pharmakon Pharmaceuticals, Inc. is registered under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) as an outsourcing facility.

The Drug Quality and Security Act, signed into law on November 27, 2013, added a new section 503B to the FDCA. Under section 503B, a compounder can elect to register as an outsourcing facility. Outsourcing facilities:

  • Must comply with current good manufacturing practice requirements;

  • Will be subject to inspection by FDA according to a risk-based schedule; and

  • Must meet certain other requirements, such as reporting adverse events and providing FDA with certain information about the products they compound.


FDA announces Pharmakon Pharmaceuticals voluntary recall of morphine sulfate 0.5 mg/mL preservative free in 0.9% sodium chloride

[2/16/2016] The U.S. Food and Drug Administration is alerting health care professionals of a voluntary recall of morphine sulfate 0.5 mg/mL preservative free in 0.9% sodium chloride, 1 mL syringe, CII, for intravenous use made and distributed by Pharmakon Pharmaceuticals, in Noblesville, Indiana, because the product is super-potent. Pharmakon initiated the voluntary recall on February 11, 2016, after receiving laboratory results showing the product was super-potent.

Injecting a patient with super-potent morphine could result in serious consequences including respiratory depression, coma, and death. Health care professionals should immediately check their medical supplies, quarantine the recalled product from Pharmakon, and not administer them to patients.

The recalled product was made on February 3, 2016, with an expiration date of March 19, 2016, and labeled with lot E52418EV11C and NDC 45183-0322-78. The recalled product was distributed to two medical facilities – one in Indiana and one in Illinois.  

On February 16, 2016, FDA was alerted of serious adverse events in three infants associated with the use of the recalled morphine sulfate products from Pharmakon. Patients who have received this drug product and who have concerns should contact their health care professionals.

FDA encourages health care professionals and patients to report adverse reactions to the FDA’s MedWatch Adverse Event Reporting program:

FDA inspected Pharmakon in March and April 2014, and issued a warning letter in May 2015. Pharmakon is registered under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) as an outsourcing facility. The Drug Quality and Security Act, signed into law on November 27, 2013, added a new section 503B to the FDCA. Under section 503B, a compounder can elect to become an outsourcing facility. Outsourcing facilities:

  • Must comply with current good manufacturing practice requirements;
  • Will be subject to inspection by FDA according to a risk-based schedule; and 
  • Must meet certain other requirements, such as reporting adverse events and providing FDA with certain information about the products they compound.

 

Page Last Updated: 05/10/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English